Loading...
Market
What will be the impact of the Proteologix acquisition on Johnson & Johnson's market share in atopic dermatitis treatment by the end of 2025?
4
Resolution / Starting Odds
Significant gain in market share • 33%
Moderate gain in market share • 34%
No significant change in market share • 33%
market share analysis and healthcare reports
Story
Johnson & Johnson to Acquire Proteologix for $850 Million, Including Dual-Targeting Antibody Drugs
May 16, 2024, 12:25 PM
Johnson & Johnson announced on Thursday that it will acquire privately held Proteologix for $850 million in cash, with potential for an additional milestone payment. The acquisition aims to bolster Johnson & Johnson's leadership in the treatment of atopic dermatitis. Proteologix brings a young roster of bispecific immunology medications, including a phase 1-ready asset targeting TSLP and dual-targeting antibody drugs. The acquisition has seen Johnson & Johnson's stock (JNJ) rise by 0.1% in pre-market trading.
View original story
Similar markets
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Standalone Unit • 25%
Merged with J&J Immunology Division • 25%
Merged with J&J Research and Development • 25%
Dissolved with Assets Redistributed • 25%
Significant increase in revenue • 25%
Moderate increase in revenue • 25%
No significant impact on revenue • 25%
Decrease in revenue • 25%
Significant increase in J&J stock price • 33%
Moderate increase in J&J stock price • 34%
No significant change in J&J stock price • 33%
Significant improvement • 25%
Moderate improvement • 25%
No significant change • 25%
Worsened financial performance • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than $500 million • 33%
$500 million - $1 billion • 33%
More than $1 billion • 34%
Less than $1 billion • 33%
Between $1 billion and $2 billion • 33%
More than $2 billion • 33%
Decrease more than 10% • 25%
Decrease less than 10% • 25%
Increase less than 10% • 25%
Increase more than 10% • 25%